Quick Answer
Keros Therapeutics, Inc. reported Total Assets of $338.02 million for the year ending 2025.
- Keros Therapeutics, Inc. showed a decrease of -45.1% in Total Assets from 2024 to 2025.
- This data is from Keros Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $60.59 million | Q2 2020: $150.44 million | Q3 2020: $138.25 million | Q1 2021: $257.73 million | Q2 2021: $243.46 million | Q3 2021: $229.96 million | Q1 2022: $235.14 million | Q2 2022: $226.66 million | Q3 2022: $252.55 million | Q1 2023: $384.44 million | Q2 2023: $356.31 million | Q3 2023: $326.25 million | Q1 2024: $485.82 million | Q2 2024: $455.02 million | Q3 2024: $579.27 million | Q1 2025: $784.56 million | Q2 2025: $757.17 million | Q3 2025: $742.78 million.
- Over the full 7 years of available data (2019 to 2025), Keros Therapeutics, Inc.'s Total Assets has grown by 2,985.5%.
- Historical annual values: Fiscal year 2025: $338.02 million | Fiscal year 2024: $615.89 million | Fiscal year 2023: $370.03 million | Fiscal year 2022: $306.78 million | Fiscal year 2021: $255.25 million | Fiscal year 2020: $269.44 million | Fiscal year 2019: $10.96 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: